AI Article Synopsis
- The study looked at how often immune-oncology (IO) therapy is used for patients with soft tissue sarcoma (STS), which is a type of cancer.
- Out of over 103,000 patients studied, only about 1,935 (or 1.9%) received IO therapy, but the use of it has increased a lot over the years.
- Patients with more serious tumors or who went to research hospitals were more likely to receive IO therapy, and further research is needed to understand how to improve its use in treating STS.
Article Abstract
Background: The role of immune-oncology (IO) therapy in soft tissue sarcoma (STS) is underexplored. This study characterized IO use in STS.
Methods: This is a retrospective analysis of patients with a soft tissue mass in the National Cancer Database, 2011-2021. Patients were categorized by IO receipt status. Groupwise testing and proportional trend tests were performed with Chi-squared tests. Multivariate logistic regression was performed to assess factors associated with IO receipt.
Results: Of the 103,092 patients with STS, 1935 (1.9 %) received or were recommended IO therapy. IO use increased 10-fold (0.24 %-2.5 % from 2011 to 2021; p < 0.0001). Patients had higher odds of receiving IO when having higher grade tumors and metastatic disease, and when treated at an academic research center (all p < 0.001).
Conclusions: IO use in STS is low but increasing and primarily used in the metastatic setting. Future studies should identify biomarkers of IO response and facilitators for treatment receipt.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11392640 | PMC |
| http://dx.doi.org/10.1016/j.amjsurg.2024.115794 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!